Hamideh Abbaspour Kasgari - Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Hamidreza Samaee - Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Shahriar Alian Samakkhah - Department of Infectious Diseases, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Parisa Moradimajd - Department of Anesthesia, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.

In late December ۲۰۱۹, a global outbreak (pandemic) of the coronavirus was reported, which WHO named ۲۰۱۹-nCoV. The virus is now spreading rapidly and has affected many countries, including Iran. There is no definitive and effective treatment for this virus yet. This report aimed to define the effect of Tocilizumab in patient with COVID-۱۹. This case report is about a ۵۲-year-old man with COVID-۱۹ that has been treated with tocilizumab. The reported patient had an acceptable improvement in oxygen saturation but no significant change in lung CT scan.  After ۳ days treatment patient with Tocilizumab, extensive bilateral lungs involvement still exist but SPO۲ level iimprovement up to ۹۰%. According to the results, this drug had a positive impact on oxygen saturation. However, we cannot be certain whether this drug positively affected the patient’s coronavirus disease.

Coronavirus, Tocilizumab, Pandemic, COVID-۱۹